Linezolid Oral Dosage and Frequency
For adults, administer linezolid 600 mg orally twice daily (every 12 hours); for children under 12 years, administer 10 mg/kg orally every 8 hours (not exceeding 600 mg per dose), and for children 12 years and older, use the adult dose of 600 mg twice daily. 1
Adult Dosing
The standard oral dose is 600 mg twice daily (BID) for most indications including:
- Complicated skin and soft tissue infections
- Pneumonia (community-acquired and nosocomial)
- Bacteremia
- Bone and joint infections (osteomyelitis, septic arthritis)
- Central nervous system infections (meningitis, brain abscess)
This dosing is supported by both IDSA guidelines 1 and FDA labeling 2, which demonstrate that oral linezolid achieves approximately 100% bioavailability, making it equivalent to intravenous administration without need for dose adjustment 2, 3.
Key pharmacokinetic considerations:
- Maximum plasma concentrations occur 1-2 hours after oral dosing 2
- Food slightly delays absorption but does not affect total exposure 2
- Linezolid may be administered without regard to meals 2
- Plasma concentrations remain above MIC90 (4.0 mg/L) for most of the 12-hour dosing interval 3
Pediatric Dosing
The dosing differs significantly by age due to developmental pharmacokinetic differences:
Children Under 12 Years
- 10 mg/kg orally every 8 hours (maximum 600 mg per dose) 1
- The every-8-hour schedule is necessary because children have 2-3 fold higher clearance rates than adults 4, 5
- This more frequent dosing achieves similar daily AUC values as the twice-daily adult regimen 2
Children 12 Years and Older
- 600 mg orally twice daily (adult dosing) 1
- By adolescence, clearance rates approach adult values 2, 5
Neonates and Infants
For neonates and young infants, clearance varies significantly:
- Full-term neonates ≥1 week old: 10 mg/kg every 8 hours 2
- Preterm neonates <1 week: Clearance is lower and similar to adults; dosing should be individualized with therapeutic drug monitoring when available 2
Important Clinical Considerations
Renal impairment: No dose adjustment is required for the parent drug in renal insufficiency, as linezolid pharmacokinetics are not significantly altered 2. However, metabolites accumulate in severe renal impairment (7-8 fold higher exposure) 2, 6. While the clinical significance remains uncertain, use caution in severe renal insufficiency. Linezolid should be administered after hemodialysis, as approximately 30% is removed during a 3-hour session 2.
Geriatric patients: No dose adjustment needed, as pharmacokinetics are not significantly altered in elderly patients 2.
Gender differences: Females have approximately 38% lower oral clearance than males, resulting in slightly higher plasma concentrations 2. However, this difference does not require dose adjustment as exposures remain within well-tolerated ranges 2.
Safety monitoring: The drug is generally well-tolerated in both adults and children 7. Common adverse events include diarrhea, nausea, vomiting, and headache 7. With prolonged use (>2 weeks), monitor for hematologic toxicity (thrombocytopenia, anemia) and peripheral neuropathy 8. Recent evidence suggests maintaining trough concentrations below 14.5-16 mg/L may reduce thrombocytopenia risk while maintaining efficacy 9.
Duration considerations: For most infections, treatment typically ranges from 7-14 days based on clinical response and infection type 1. For multidrug-resistant tuberculosis, specialized prolonged regimens are used with dose modifications to balance efficacy and toxicity 10.